ADXN.S
Latest Trade
--Change
--(--)Today's Range
-
--52 Week Range
-
--As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay
Previous Close | -- |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 0.47 |
Today's High | -- |
Today's Low | -- |
52 Week High | -- |
52 Week Low | -- |
Shares Out (MIL) | 26.49 |
Market Cap (MIL) | 58.96 |
Forward P/E | -4.27 |
Dividend (Yield %) | -- |
Addex Therapeutics H1 Net Profit Swings To Loss Of CHF 7.5 Mln
Addex Therapeutics Increases Issued Share Capital
Addex Therapeutics FY Net Loss At CHF 1.6 Mln
Addex Therapeutics Ltd is a Switzerland-based company, that discovers and develops a class of small molecule drugs, allosteric modulators. Its two products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by the Company to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by its partner Janssen Pharmaceuticals Inc. to treat schizophrenia. It also is advancing several preclinical programs, including GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression, and FSHR/LHR NAM for sex hormone dependent tumors and reproductive system disorders. In addition, it has discovery programs to identify allosteric modulators of receptor tyrosine kinase superfamily
Industry
Biotechnology & Drugs
Executive Leadership
Vincent Lawton
Chairman of the Board of Directors
Tim Dyer
Chief Executive Officer, Member of the Executive Board, Member of the Board of Directors
Roger G. Mills
Member of the Executive Board, Chief Medical Officer, Member of the Board of Directors
Robert Luetjens
Member of the Executive Board, Head of Discovery
Jean-Philippe Rocher
Member of the Executive Board, Head of Discovery
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 23.01 |
Price To Book (MRQ) | 1.47 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 1.23 |
LT Debt To Equity (MRQ) | 0.35 |
Return on Investment (TTM) | -30.34 |
Return on Equity (TTM) | -27.86 |
* SUBMITS REGISTRATION STATEMENT WITH U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* HAS INCREASED ITS CAPITAL FROM 28,564,031 TO 32,848,635 THROUGH THE ISSUE OF 4,284,604 NEW REGISTERED SHARES
* NET LOSS FOR 2018 WAS CHF1.6 MILLION COMPARED TO CHF3.2 MILLION FOR 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* FY NET CASH FROM OPERATING ACTIVITIES OF CHF1.9 MILLION (2017: CHF1.2 MILLION)
* ADDEX AND INDIVIOR TO ACCELERATE ADDITIONAL GABAB PAM COMPOUNDS FOR ADDICTION AS INDIVIOR ELECTS TO STOP DEVELOPMENT OF ADX71441 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* COMPLETED FIRST HALF 2018 WITH CHF43.6 MILLION IN CASH AND CASH EQUIVALENTS
* REG-ADDEX ADX10061 RECEIVES £1.2 MILLION FUNDING FOR MANUFACTURE AND INVESTIGATOR LED CLINICAL STUDIES AS PART OF THE TOOLS FOR HUMAN DRUG AND BRAIN RESEARCH (THUNDR2) INITIATIVE FROM THE WELLCOME TRUST Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* ADDEX’S SELECTIVE MGLU2 PAM ADX71149 SHOWS PROMISE IN TREATING SEVERE PANIC DISORDERS AND PTSD Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* NET LOSS FOR 2017 FINANCIAL YEAR WAS CHF3.3 MILLION COMPARED TO CHF3.1 MILLION FOR 2016
* LAUNCHES CHF40 MILLION CAPITAL INCREASE WITH COMMITMENT FROM SPECIALIST US HEALTHCARE INVESTORS
* CASH POSITION OF CHF6.5 MILLION AS OF 31 JANUARY 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* REG-ADDEX AND INDIVIOR SIGN STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF GABAB PAMS AS ADDICTION TREATMENTS
* REG-ADDEX THERAPEUTICS ADX71441 PROGRAM AWARDED $5.3 MILLION GRANT FROM US NATIONAL INSTITUTE ON DRUG ABUSE TO SUPPORT HUMAN STUDIES FOR THE TREATMENT OF COCAINE USE DISORDER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* NET LOSS INCREASED TO CHF1.8 MILLION IN THE FIRST HALF OF 2017 FROM CHF1.5 MILLION IN THE FIRST HALF OF 2016
* FY net loss for the year decreased significantly to 3.1 million Swiss francs ($3.09 million)for 2016, compared to 4.2 million Swiss francs for 2015
* Raises 3.0 million Swiss francs ($2.98 million) through private placement of treasury shares and extends cash runway through 2018
* Addex awarded $835,000 grant from Michael J. Fox foundation to advance TrkB pams for treatment of Parkinson's Disease Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Addex ADX71441 demonstrates statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Says Addex appoints biopharmaceutical industry veteran, Roger G. Mills, M.D., as Chief Medical Officer Source text - http://bit.ly/2gNzjj5 Further company coverage: (Gdynia Newsroom)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.